Company
Abbvie Inc
NYSE:ABBV
Abbvie Inc is a diversified research-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies.
44 stories
AT&T and Discovery raise US$30bn in bond offering
The debt offering is fourth highest in history as investors order more than £106bn
UK to open up biosimilar drugs market with change to rules
Around 80% of the most expensive drugs used by the NHS are biologics
Not too late for coronavirus vaccines, new drugs as outbreak “likely” to repeat
Experts say the most effective treatment for now would be repurposing existing drugs, but vaccines and new formulations are still welcome
Queensland Uni joins US biotechs in search for coronavirus vaccine
NASDAQ-listed Inovio Pharmaceuticals and Moderna have been awarded funds to develop a vaccine
Pharma stocks head south as Trump forces them to display drug prices in TV ads
“Drug companies have to come clean about their prices in TV ads. If drug companies are ashamed of those prices – lower them!”
Voyager Therapeutics stock flies after AbbVie collaboration
The collaboration is potentially valued at over $1 billion
US billionaire Robert Duggan to invest US$25mln into Summit Therapeutics
Duggan was the boss of Pharmacyclics and oversaw the company’s US$21bn sale to US pharma giant AbbVie back in 2015
EARLY MOVERS: The Children's Place shares sink on weak earnings; AbbVie slides after drug test cut short
Weak results and a suspension of a key drug test hits the stock of two companies as trading resumes in the US after a one-day break
US giant AbbVie to fund trial of genedrive's hep C test
genedrive thinks its simple out-reach test can help to cure hepatitis C in recovering heroin addicts, people who generally don’t like going to the doctors
AbbVie posts 2Q profit, revenue beats on healthy sales of arthritis top-seller Humira
Drugmaker raises 2018 EPS guidance to between US$7.76 to US$7.86 from between US$7.66 and US$7.76
Shires shares spike 4% after Takeda revises £43bn bid
Has the Japanese drugs giant sweetened further the cash element of its £43bn offer?
US benchmarks plummet as fears rise about a US-China trade war
By the market’s close in NY, the Dow Jones had seen its worst day since the eighth of February
Biogen and AbbVie halt sales of Zinbryta multiple sclerosis drug due to safety concerns
Biogen and AbbVie have halted sales of the multiple sclerosis treatment following several reports of brain inflammation in people who took the drug
Strong Humira sales lead to Q4 beat for AbbVie
The drugmaker also upped its earnings forecasts for 2018 following the strong performance in the final few months of 2017
Markets storm higher as economists look beyond the headline GDP figure
Fourth quarter growth in the economic "was clearly driven by the private sector," according to the Wells Fargo Economics Group.
Abbvie advances as it raises full year outlook
Earnings per share (EPS) for the three months came in at US$1.41 a share, beating consensus estimates of US$1.39 each.
Abbvie shares rising in New York on eczema drug news
The news led to a fall in rival Regeneron (NASDAQ:REGN), which shed over 5.6%
Abbvie's rheumatoid arthritis treatment achieves positive results in Phase 3 test
The test met the primary endpoints and key secondary endpoints
AbbVie's revenue miss clouds strong Humira US sales
AbbVie Inc shares were lower on Friday after the pharma reported quarterly adjusted revenue that missed analysts' estimates as weaker-than-expected sales of its hepatitis C treatment and cancer therapy overshadowed strong US demand for its
Redx Pharma's BTK inhibitor programme should spark partner interest
Last week, Redx said it had selected RXC005 - a Bruton's tyrosine kinase inhibitor - to take into clinical development.
Archive
Pfizer, Etsy and eBay on brokers’ radars
Pfizer bruised by a downgrade from Jefferies but Wedbush assume coverage of eCommerce names eBay and Etsy
Infinity Pharma shares dumped after Phase II trial misses expectations
Infinity Pharmaceuticals Inc shares are dumped after the biotech said its lead drug duvelisib fell short of Phase II expectations, forcing it to pause work with partner AbbVie
U.S. Risers & Fallers: Microsoft, Visa, MasterCard, Whirlpool, Amazon, Chevron, AbbVie
Below are some of the main news-driven share price changes as at 11:41 a.m. in New York.
Broker snap, including Abbvie, Valeant Pharmaceuticals, Boeing and Genesee & Wyoming
Genesee & Wyoming was upgraded by Macquarie today....
Archive
Wall Street wavers amid earnings, economic reports
All three major indices failed to hold gains on Friday
Stocks sleepwalk towards the end of the month
Despite some fairly chunky movements by a few blue-chips, their effects are cancelled out and stock market indexes are little changed
U.S. Risers/Fallers: LinkedIn, SolarCity, Valeant, Starbucks, KeyCorp, Newell Rubbermaid, AbbVie
Below are the main news driven share price changes at 12:01 p.m. in New York on Friday:
US stocks' bright start soon fades
Stocks made a brief attempt to shake off yesterday's lethargy but soon headed south
AbbVie surges after raising long-term guidance
This time last year the drugs maker was getting cold feet over a blockbuster bid for Shire
Wall Street slides as biotech, commodities weigh; Biogen, TripAdvisor sink
U.S. stock indexes fell Friday as investors dumped shares of biotechnology companies after disappointing results from Biogen and as materials and energy stocks continued to lag. The S&P 500 (INDEXSP:.INX) slid 1.1 percent to 2,077.95 at